Why Is Tyra Biosciences Stock Sinking Wednesday? - Tyra Biosciences (NASDAQ:TYRA)
Tyra Biosciences (NASDAQ:TYRA) shares fell 21.6% after Phase 2 trial results for dabogratinib showed an 86% overall response rate in patients with target exposure, but a 57% complete response rate at 60 mg, below analyst expectations of 70-80%. The company plans to advance to Phase 3 development and expand the study to a 70 mg cohort. Initial upper tract urothelial cancer study results were positive.
How this was made
The 30-second read
Why it matters
The Phase 2 readout provides the first efficacy data for dabogratinib, directly influencing market perception and share price.
Market read
New clinical data caused a sharp intra‑day decline, highlighting immediate trading relevance for TYRA and peers.
What to watch
The trial identified a clear exposure‑response relationship and plans for a 70 mg cohort, which could improve future outcomes.
Background
Tyra Biosciences is a Nasdaq‑listed biotech focused on FGFR3‑altered bladder cancer therapies.
Ticker impact
Tyra Biosciences disclosed Phase 2 SURF302 trial results showing lower-than-expected complete response rates, triggering a 21.6% share drop.
Further downside pressure if Phase 3 outlook remains uncertain.
The trial's 57% CR rate versus expected 70‑80% is a material new fact that moved the stock sharply on the day of release.
Market effects
Biotech sector may see heightened scrutiny of early‑stage oncology trials.
U.S. biotech investors could reassess risk on similar FGFR3‑targeted programs.
Limited to companies with comparable bladder cancer pipelines.
Counterpoint
Some investors may view the 86% overall response as a positive signal despite lower CR, supporting a longer‑term hold.
Key entities
- CompanyTyra Biosciences Inc.
Developer of dabogratinib for bladder cancer.
- AnalystWilliam Blair
Commented on the stock plunge due to trial results.
